AFT Pharmaceuticals

[trader_jackson]

wow , this 12% movement today really goes to show how emotive the market is !!
just a little toke(n) of cannabis and some users are pushing the price higher.

disc hold (so I am happy about this - but at the same time see it as kind of ridiculous)

I don't see it as too ridiculous at all... what is ridiculous is how the share price went down from $2 (already a record low) to $1.70 in a matter of weeks... down 15% off the back of no bad news

If it was to go to $2.50 today, then I might get the ridiculous label out.

What is more intriguing is the volume - no at 17k - that is over 10x more than normal with the day yet to finish, and 51k+ buyers still lined up (also much more interest than normal)... so there is some positives, the price going up 12% is simply a recovery of unnecessary lost ground... but thats the price you (can sometimes) pay with an illiquid stock that is (currently) AFT.

[winner69]

This the same Edison Research calling Rubicon a couple of years ago undervalued (when the SP was twice as it is now), predicting a breakthrough for PEB anytime soon (since at least 2016) and putting CRP on above $1?

When you down on a stock you’re as bad as bull...

Anything else we should know about besides can’t call this the bottom, anybody can grow marijuana, AFT has no moat and Edison rubbish ...

[winner69]

Tj ...that EXL on the ASX trades at about 20 times revenues ..mind you they sell hemp related stuff as well

AFT as a global medical cannabis supplier has a nice ring to it.

[pg0220]

Tj ...that EXL on the ASX trades at about 20 times revenues ..mind you they sell hemp related stuff as well

Their balance sheet is very strong tho.

[BlackPeter]

When you down on a stock you’re as bad as bull...

Anything else we should know about besides can’t call this the bottom, anybody can grow marijuana, AFT has no moat and Edison rubbish ...

Ouch this hurts. I thought one of the clear differences to the other poster might be that I typically explain my rationale other than "my analysis says".

Apologies if I hurt your feelings by not sufficiently considering what the endowment effect might have done to you. But apart from that - was anything I stated incorrect?

[peat]

was anything I stated incorrect?

The ease of growing marijuana is irrelevant

Its the commercialisation of marijuana and dealing with regulatory requirements where AFT will potentially add value.

[BlackPeter]

The ease of growing marijuana is irrelevant

Its the commercialisation of marijuana and dealing with regulatory requirements where AFT will potentially add value.

Fair enough - not every backyard grower might be able to compete, but really - how difficult will this be for any other pharma company compared to the hoops they typically have to jump through?

[peat]

but really - how difficult will this be for any other pharma company compared to the hoops they typically have to jump through?

same might be said of combining paracetemol and ibuprofen calling it Maxigesic and patenting it and licensing it but it seems to sell very well according to all the chemists I've asked.

[BlackPeter]

same might be said of combining paracetemol and ibuprofen calling it Maxigesic and patenting it and licensing it but it seems to sell very well according to all the chemists I've asked.

True. Question though is whether it is doing as well on the international market. NZ is one of the world leaders in (per head of population) painkiller consumption.

[trader_jackson]

True. Question though is whether it is doing as well on the international market. NZ is one of the world leaders in (per head of population) painkiller consumption.

It is doing exceptionally well in Australia (and has been for years)... both NZ and Australia grew two fold and sales in "sales in this half made to Italy, Ireland, Israel, Iraq, United Arab Emirates and the CentralAmerican Common Market (CACM)" up 70% and Southeast Asia revenue grew by 81%, so many other parts of the world are accepting Maxigesic very, very well... and that is 'just the beginning' with 'Further launches are imminent and are dictated by regulatory timelines" for the 'rest of world' category.